Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma, B-Cell
In brief
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
Key facts
- Study ID
- NCT00577629
- Run by
- Duke University
- People needed
- 39
- Starts
- 2005-06-18
- Expected to finish
- 2016-11-03
- Last updated by the study team
- 2017-05-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Untreated, biopsy proven B-cell non-Hodgkin's lymphoma
- Age >/= 18 years
- No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. The patient cannot have been exposed to chemotherapy to treat any of these diseases for at least 3 years prior to study entry.
- Meet staging studies and laboratory tests prior to induction, consolidation and radioimmunotherapy.
You may not qualify if…
- Significant medical and/or psychiatric illness which may compromise planned treatment;
- Pregnant or lactating;
- HIV-infection.
- Patients with follicular lymphoma grade 1, 2 or 3A are not eligible for this trial.
Where it is running
- Duke University Medical Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.